PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: Updated survival data

Immunotherapy

Volumn 9, Issue 6, 2017, Pages 499-506

  Aguiar, Pedro N ^a   De Mello, Ramon Andrade ^b,c   Hall, Peter ^d   Tadokoro, Hakaru ^a   De Lima Lopes, Gilberto ^e  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF ALGARVE   (Portugal)

^c CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF MIAMI   (United States)

Author keywords

anti PDL1; clinical trials; lung cancer; meta analysis; nivolumab; non small lung cancer; PD1; pembrolizumab

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; NIVOLUMAB; PDCD1 PROTEIN, HUMAN; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR;

ADVANCED CANCER; CANCER SURVIVAL; HAZARD RATIO; HUMAN; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SURVIVAL ANALYSIS; TREATMENT RESPONSE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; METABOLISM; MORTALITY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; SURVIVAL ANALYSIS;

EID: 85019018267     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2016-0150     Document Type: Review

References (30)

1. IARC. Fact Sheets by Population. http://globocan.iarc.fr/ Pages/fact-sheets-population.aspx
2. Garon EB, Ciuleanu TE, Arrieta O et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised Phase 3 trial. Lancet 384(9944), 665-673 (2014)
3. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372(21), 2018-28 (2015). www.ncbi.nlm.nih.gov/ pubmed/25891174
4. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627-39 (2015)
5. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373(2), 123-35 (2015)
6. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin. Cancer Res. 18(24), 6580-6587 (2012)
7. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009)
8. Aguiar PN, Santoro IL, Tadokoro H et al. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy 8(4), 479-488 (2016)
9. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92(3), 205-216 (2000)
10. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15(23), 7412-7420 (2009)
11. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8(1), 16 (2007)
12. Rizvi NA, Mazières J, Planchard D et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a Phase 2, single-arm trial. Lancet Oncol. 16(3), 257-265 (2015)
13. Gettinger SN, Horn L, Gandhi L et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 33(18), 2004-2012 (2015)
14. Fehrenbacher L, Spira A, Ballinger M et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, Phase 2 randomised controlled trial. Lancet 6736(16), 1-10 (2016)
15. Horn L, Spigel DR, Gettinger SN et al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a Phase Ia study. Presented at: ASCO Annual Meeting. J. Clin. Oncol. 33, (Suppl. Abstract 8034). (2015)
16. Barlesi F, Park K, Ciardiello F et al. Primary analysis from OAK, a randomized Phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. Ann. Oncol. 27(Suppl. 6), LBA44PR (2016)
17. Gettinger S, Rizvi NA, Chow LQ et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. (34(25), 2980-2987 2016)
18. Hellmann M, Gettinger S, Goldman J et al. CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. Presented at: 2016 ASCO Annual Meeting. J. Clin. Oncol. ChicagoUSA, 2-6 June (2016). http://meetinglibrary.asco. org/content/163524-176
19. Rizvi NA, Brahmer JR, Ou S-H et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J. Clin Oncol. (2015). http:// meetinglibrary.asco.org/content/108561?media=vm
20. Antonia S, Goldberg SB, Balmanoukian A et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: A multicentre, Phase 1b study. Lancet Oncol. 17(3), 299-308 (2016). http://dx.doi. org/10.1016/S1470-2045(15)00544-6
21. Gulley JL, Spigel D, Kelly K et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a Phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. J. Clin. Oncol. (2015). http://meetinglibrary.asco.org/ content/147880-156
22. Liu SV, Powderly JD, Camidge DR et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Presented at: ASCO Annual Meeting. J. Clin. Oncol. Chicago, USA (2015). http:// meetinglibrary.asco.org/content/148182-156
23. Masters GA, Temin S, Azzoli CG et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin. Oncol. 33(30), 3488-515 (2015). www.ncbi.nlm.nih. gov/pubmed/26324367
24. Novello S, Barlesi F, Califano R et al. Metastatic non small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann. Oncol.27(Suppl. 5), v1-v27 (2016)
25. Passiglia F, Bronte G, Bazan V et al. PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget 7(15), 19738-19747, (2016). www.ncbi. nlm.nih.gov/pubmed/26918451
26. Abdel-Rahman O. Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. Crit. Rev. Oncol. Hematol. 101, 75-85 (2016). www.ncbi.nlm.nih.gov/ pubmed/26969107
27. Reck M, Rodríguez-Abreu D, Robinson AG et al. KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 50%. Ann. Oncol. 27(Suppl. 6), LBA8PR (2016)
28. Socinski M, Creelan B, Horn L et al. NSCLC, metastaticCheckMate 026: A Phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/ recurrent programmed death ligand 1 (PD-L1)-positive NSCLC. Ann. Oncol. 27(Suppl. 6), LBA7PR (2016)
29. Luke L, Bao R, Spranger S, Sweis R, Gajewski T. Correlation of WNT/β-catenin pathway activation with immune exclusion across most human cancers. Presented at: ASCO Annual Meeting. J. Clin. Oncol. Chicago (2016). http:// meetinglibrary.asco.org/content/166812-176
30. Funt S, Charen A, Yusko E et al. Correlation of peripheral and intratumoral T-cell receptor (TCR) clonality with clinical outcomes in patients with metastatic urothelial cancer (mUC) treated with atezolizumab. [Internet]. Presented at: ASCO Annual Meeting. J. Clin. Oncol. Chicago (2016). http://meetinglibrary.asco.org/content/167312-176